CagriSema

News

CagriSema helps women lose 25% of their weight in study

Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women.

News

Under pressure, Novo lays out blockbuster launch plans

Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.

News

Novo fails to shrug off investor concern at Q2 update

Novo Nordisk's better-than-expected second-quarter revenues can't outweigh worries about oral Wegovy growth and another CagriSema disappointment.

News

US judge says Novo Nordisk must face lawsuit over CagriSema

A US judge has ruled that Novo Nordisk must face a lawsuit claiming it defrauded investors with misleading statements about a pivotal CagriSema study.

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

CagriSema helps women lose 25% of their weight in study

Under pressure, Novo lays out blockbuster launch plans

Novo fails to shrug off investor concern at Q2 update

US judge says Novo Nordisk must face lawsuit over CagriSema

ADA: Lilly's weight-loss reveal, and wannabes display wares

After CagriSema blow, Novo reveals data for obesity 'triple'

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

CagriSema

Editor's Picks